Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
<h4>Background</h4>Buruli ulcer (BU) is a skin neglected tropical disease (NTD) caused by Mycobacterium ulcerans. WHO-recommended treatment requires 8-weeks of daily rifampicin (RIF) and clarithromycin (CLA) with wound care. Treatment compliance may be challenging due to socioeconomic de...
Saved in:
Main Authors: | Emma Sáez-López (Author), Ana C Millán-Placer (Author), Ainhoa Lucía (Author), Santiago Ramón-García (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
by: Deepak Almeida, et al.
Published: (2011) -
Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
by: Daniel P O'Brien, et al.
Published: (2012) -
Bioequivalence of amoxicillin and clavulanic acid tablet
by: Yuwadee Sirisomboon
Published: (2006) -
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
by: Deepak V Almeida, et al.
Published: (2013) -
Amoxicillin and clavulanate potassium related Leucocytoclastic vasculitis
by: Snehal Balvant Lunge, et al.
Published: (2014)